ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Odyssey Semiconductor Technologies Inc (CE)

Odyssey Semiconductor Technologies Inc (CE) (ODII)

0.074
0.00
(0.00%)
Cerrado 31 Julio 3:00PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
0.074
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.025 Rango de 52 semanas 0.5097
Capitalización de Mercado [m]
Precio Anterior
0.074
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
27,397
Acciones en circulación
12,726,911
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.20
Beneficio por acción (BPA)
-0.35
turnover
292k
Beneficio neto
-4.47M

Acerca de Odyssey Semiconductor Technologies Inc (CE)

Existing high voltage switching technology used in applications such as Electric Vehicles or Solar Energy is based on silicon carbide (SiC). However, the material properties of gallium nitride (GaN) make it a far superior option over SiC for high voltage power switching applications. To date, GaN pr... Existing high voltage switching technology used in applications such as Electric Vehicles or Solar Energy is based on silicon carbide (SiC). However, the material properties of gallium nitride (GaN) make it a far superior option over SiC for high voltage power switching applications. To date, GaN processing technology has not been able to produce a viable GaN high voltage switching transistor operating above 1,000 V. Current devices are largely horizontal conduction devices based on radio frequency (RF) designs modified to operate at high voltage. These designs are not scalable beyond 1,000 V operating voltage, which limits their use to low voltage, consumer electronics applications. Odyssey Semiconductor's unique and proprietary GaN processing technology allows for the realization of vertical current conduction GaN devices, extending application voltages from 1,000 V to over 10,000V. This allows GaN power switching devices to extend well beyond the consumer electronics application space and into more demanding applications such as Electric Vehicles, Solar Energy, Industrial Motor Control, and Energy Grid applications. Mostrar más

Sector
Semiconductor,related Device
Industria
Semiconductor,related Device
Sede
Lewes, Delaware, USA
Fundado
1970
Odyssey Semiconductor Technologies Inc (CE) is listed in the Semiconductor,related Device sector of the OTCMarkets with ticker ODII. The last closing price for Odyssey Semiconductor Te... (CE) was US$0.07. Over the last year, Odyssey Semiconductor Te... (CE) shares have traded in a share price range of US$ 0.025 to US$ 0.5097.

Odyssey Semiconductor Te... (CE) currently has 12,726,911 shares in issue. The market capitalisation of Odyssey Semiconductor Te... (CE) is US$941,791.41 . Odyssey Semiconductor Te... (CE) has a price to earnings ratio (PE ratio) of -0.20.

ODII Últimas noticias

STENTYS : hausse de 28% du chiffre d’affaires au 1er trimestre 2015

Regulatory News : STENTYS (Paris:STNT) (FR0010949404 — STNT – éligible PEA PME), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire...

STENTYS : mise à disposition des documents préparatoires à l’assemblée générale mixte du 5 mai 2015

Regulatory News: STENTYS (Paris:STNT) (FR0010949404 — STNT – éligible PEA PME), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire...

STENTYS : mise à disposition du rapport financier annuel 2014

Regulatory News: STENTYS (FR0010949404 — STNT – éligible PEA PME), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire, informe ses...

STENTYS : Résultats annuels 2014

Chiffre d’affaires annuel en progression de +13% Trésorerie robuste de 18,6 M€ permettant le déploiement commercial de la nouvelle gamme de produits Provision sur l’étude...

STENTYS réaffirme son éligibilité au PEA-PME pour 2015/2016

Regulatory News: STENTYS (Paris:STNT) (FR0010949404 — STNT — éligible PEA-PME), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire...

Stentys : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du cod...

Situation au 28 février 2015 Regulatory News: Stentys (Paris:STNT): Nombre de titres composant le capital en circulation       11 721 371 Nombre de...

STENTYS : les résultats de la plus grande étude dans l’infarctus du myocarde publiés dans EuroIntervention

L’étude APPOSITION III a montré l’excellent niveau de sécurité de la technologie auto-apposante Regulatory News: STENTYS (Paris:STNT) (FR0010949404 — STNT — éligible PEA PME...

STENTYS annonce la publication d’une nouvelle étude sur le stent auto-apposant dans le traitement de l’artère principal...

L’étude publiée en ligne dans la revue Catheterization and Cardiovascular Interventions démontre la supériorité du stent auto-apposant à élargir le tronc commun Regulatory News :...

STENTYS étend l’usage du premier stent actif auto-apposant aux maladies artérielles des membres inférieurs

Une étude clinique démontre la capacité de STENTYS à éviter l’amputation dans 99% des cas Regulatory News : STENTYS (Paris:STNT) (FR0010949404 — STNT – éligible PEA PME), société de...

STENTYS : Bilan semestriel du contrat de liquidité conclu avec la société de bourse GILBERT DUPONT

Regulatory News : Au titre du contrat de liquidité confié par la société STENTYS (Paris:STNT) à la Société de Bourse Gilbert Dupont, à la date du 31 décembre 2014, les moyens suivants...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1000.0740.0740.0746000.074CS
4-0.001-1.333333333330.0750.08250.07467480.07593803CS
120.0022.777777777780.0720.11530.07273970.07649876CS
260.001051.439342015080.072950.1620.05336780.06821705CS
52-0.426-85.20.50.50970.025300540.07681259CS
156-2.601-97.23364485982.6752.80.025131740.60511952CS
260-4.026-98.19512195124.160.025126981.09352728CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ALDAAtlantica Inc (PK)
US$ 0.0106
(1,059,900.00%)
11.73k
NOKPFNok Airlines Public Company Ltd (CE)
US$ 0.01
(999,900.00%)
100
OIBZQOi SA (CE)
US$ 0.1697
(84,750.00%)
400
ATYGAtlas Technology Group Inc (PK)
US$ 0.0002
(19,900.00%)
35k
AFIIQArmstrong Flooring Inc (CE)
US$ 0.0002
(19,900.00%)
278
CLVRClever Leaves Holdings Inc (CE)
US$ 0.000001
(-100.00%)
225
CNCNChun Can Capital Group (CE)
US$ 0.000001
(-100.00%)
1,000
CGIPCeladon Group Inc (CE)
US$ 0.000001
(-99.81%)
5.28k
LMDXFLumiraDx Ltd (CE)
US$ 0.000001
(-99.80%)
150
IDXADIDEX Biometrics ASA (CE)
US$ 0.0002
(-99.80%)
5k
GMPRGourmet Provisions International Corporation (PK)
US$ 0.0001
(-33.33%)
437.02M
KGKGKona Gold Beverage Inc (PK)
US$ 0.0006
(0.00%)
201.47M
HIRUHiru Corporation (PK)
US$ 0.0032
(-21.95%)
151.12M
SIRCSolar Integrated Roofing Corporation (PK)
US$ 0.0001
(0.00%)
105.17M
HMBLHUMBL Inc (PK)
US$ 0.00025
(25.00%)
100.46M
Nebuchadnezzar Nebuchadnezzar 3 minutos hace
whatever you say bud ;)
HIRU
blossom3 blossom3 3 minutos hace
Ackman is full of 💩💩💩💩💩
FNMA
glenn1919 glenn1919 3 minutos hace
CTNT..........................https://stockcharts.com/h-sc/ui?s=CTNT&p=W&b=5&g=0&id=p86431144783
CTNT
MasterBlastr MasterBlastr 4 minutos hace
Updated weather forecast - slight chance of rain, 5-10 mph winds pretty much through the tourney. Little chance of raw sewage spilling over onto the course. They spend $1.5 billion to clean up the Seine for the Olympics and a rain storm causes the sewage system to overflow and dump into the river.
SC8 SC8 4 minutos hace
Most likely the containment concern remains unresolved. That's most likely why they had to do more rabbits and took forever to write up the results. It's not easy to put lipstick on a pig. In any case, it's clear FDA wants a risk/benefit analysis cuz there are substantial risks to patient. Keep
RDGL
Sauerkraut Sauerkraut 4 minutos hace
But...but....but....it looks good in PR's for people who don't know.....glty
IQST
glenn1919 glenn1919 4 minutos hace
ATCH.........................https://stockcharts.com/h-sc/ui?s=ATCH&p=W&b=5&g=0&id=p86431144783
ATCH
crazy horse 0 crazy horse 0 5 minutos hace
Why does the FBI keep lying about the attempted assassination of Trump?

If Donald Trump manages to return to the White House, he had better plan on dismantling the FBI brick by brick. If he doesn’t, the bureau will bury him alive.

https://www.theblaze.com/columns/opi
arizona1 arizona1 5 minutos hace
Over years i've never seen evidence Trump used cocaine

Noel Casler talks about it and Trump has never sued him as far as I know.

[yt]N60ceYRlY2I[/yt]
Greedy G Greedy G 5 minutos hace
~META beat NVDA going to rocket some more, market up up & away imo
NVDA
DewDiligence DewDiligence 5 minutos hace
ALX -25%/AH on phase-2 data in gastric cancer:

https://www.globenewswire.com/news-release/2024/07/31/2922206/0/en/ALX-Oncology-Reports-Topline-Data-From-ASPEN-06-Phase-2-Trial-Demonstrating-Evorpacept-Improves-Tumor-Response-in-Patients-With-HER2-Positive-Gastric-Cancer.html In the f
Ricorich Ricorich 5 minutos hace
Lol you're dreaming, is impossible to find a great one like HIRU
HIRU
glenn1919 glenn1919 5 minutos hace
IMRX........................https://stockcharts.com/h-sc/ui?s=IMRX&p=W&b=5&g=0&id=p86431144783
IMRX
Harbor6460 Harbor6460 5 minutos hace
Sell if u want. It appears it doesn’t matter. Loll
CVNA
WillForeall WillForeall 5 minutos hace
Only if the perspective is of a flipping mindset. But not everyone is so talented lolzzz
HIRU
Chromosome Chromosome 5 minutos hace
RMB, that’s another way to interpret. But a 25% reduction in overall business (assuming 2/3 Medicare) means virtually all their commercial sales came from CVS which I have a hard time imagining.
But to your point, I wish one of the analysts would have clarified this once and for all.
CVS
Dubster watching Dubster watching 6 minutos hace
$9.38 target to re-enter
TSDD
Filterthenoise Filterthenoise 7 minutos hace
Framework looks set and merger shares about to be doled out upon approval
RNVA
crazy horse 0 crazy horse 0 7 minutos hace
'Disgraceful': Trump torches 'very rude' ABC News reporter at National Association of Black Journalists convention

https://www.theblaze.com/news/disgraceful-trump-torches-very-rude-abc-news-reporter-at-national-association-of-black-journalists-convention?utm_source=theblaze-breaking&
Lime Time Lime Time 7 minutos hace
It might be a good idea to accumulate and hold here. FINRA won't allow reverse split, so it's only up from these prices 🚀

Waiting for a pump 8k 🚀
ATYG
op1 op1 7 minutos hace
It would of course have to be a company that would roll up into wddd as another business which has existing revenue and profits to see dollars
Wddd is still sec compliant and if the up listing is finalized that would be tell tale along with other announcements
And maybe it would be t
WDDD

Su Consulta Reciente

Delayed Upgrade Clock